Characteristics | All Patients, n = 162 | Women, n = 116 | Men, n = 46 |
---|---|---|---|
Age at RA diagnosis (yrs) | 55.76 ± 15.01 | 54.14 ± 15.20 | 59.84 ± 13.84* |
DAS28 | 5.85 ± 0.043 | 5.78 ± 0.942 | 6.01 ± 1.26 |
Number of swollen joints | 6.0 (0–23) | 6.0 (0–22) | 8.0 (2–23) |
Number of tender joints | 10.0 (0–27) | 10.0 (0–25) | 12.0 (3–27) |
Duration of morning stiffness (min) | 105.93 ± 86.86 | 101.28 ± 86.10 | 118.00 ± 88.69 |
Global patient assessment | 56.66 ± 21.89 | 56.69 ± 20.66 | 56.56 ± 25.06 |
Patient pain assessment | 6.10 ± 2.08 | 6.13 ± 2.16 | 6.02 ± 1.89 |
HAQ score | 1.37 ± 0.66 | 1.36 ± 0.65 | 1.40 ± 0.72 |
CRP (mg/dl) | 6.57 ± 18.32 | 6.16 ± 19.40 | 7.64 ± 15.35 |
ESR (mm/h) | 41.96 ± 26.01 | 40.75 ± 24.24 | 45.07 ± 30.19 |
Presence of HLA-DRB1 SE | 78 (53.1) | 53 (50.0) | 25 (61.0) |
RF positivity | 100 (61.7) | 71 (61.2) | 29 (63.0) |
Anti-CCP positivity | 90 (55.6) | 63 (54.3) | 27 (58.7) |
↵* p = 0.029. DAS28: Disease Activity Score 28; HAQ: Health Assessment Questionnaire; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; CCP: cyclic citrullinated peptides.